Abstract:10116 Background: This phase III double-blind study was conducted to provide bridging data to the available efficacy and safety data of denosumab (DmAb) from global skeletal-related events (SRE)-prevention studies, by comparing DmAb with zoledronic acid (ZA). Methods: Patients aged ≥18 years who had a confirmed solid tumor, evidence of ≥1 bone metastasis and ECOG score 0-2 were enrolled. Patients were randomized (2:1) to receive either DmAb 120 mg subcutaneously every 4 weeks (Q4W) or ZA 4 mg intravenously Q4W for 49 weeks (wks) and are being followed up to Wk 73. The primary endpoint was percent change in urinary amino-terminal cross-linking telopeptide of type I collagen, corrected for urine creatinine (uNTx/uCr) from baseline (BL) to 13 wks. Other endpoints were percent change in bone-specific alkaline phosphatase (S-BALP) from BL to 13 wks and time to first on-study SRE. Safety and tolerability were assessed including collecting all adverse events (AEs) and performing vital signs measurement and a standard panel of laboratory tests. Results: A total of 485 (DmAb=326, ZA=159) pts were randomized; 90% of pts had either completed the study or withdrawn by planned data cut-off (29 February 2016). Mean (SD) age of pts was 53.9 (11.38) years; 67% pts were women, 93% Chinese, 50% had breast cancer and 27% had non-small cell lung cancer. The mean change in uNTx/uCr from BL to Wk 13 was -81.9% for DmAb and -75.2% for ZA (ANCOVA; p<0.0001). The median change in S-BALP from BL to Wk 13 was -36.8% (DmAb) and -30.3% (ZA) (p=0.027). Rate of developing any on-study SRE within the first year after initializing treatment was lower in pts receiving DmAb vs ZA (4.9% vs 6.3%) without statistical significance. Incidence of AEs was similar in DmAb and ZA groups (89% vs 91%), with most common AEs being anemia (25% vs 24%), white blood cell count decreased (21% vs 24%), and pyrexia (13% vs 21%); overall incidence of serious AEs: 14% vs 9%. One serious AE (muscular weakness) was reported as related to study treatment. Conclusions: DmAb was found to be superior than ZA in reducinguNTx/uCr in overall and Chinese pts. No new safety concerns were identified with DmAb. Clinical trial information: NCT01920568.

Denosumab Versus Risedronate in Glucocorticoid‐Induced Osteoporosis: Final Results of a Twenty‐Four–Month Randomized, Double‐Blind, Double‐Dummy Trial

Efficacy and Safety of Denosumab in Postmenopausal Women with Osteoporosis

Comparison of denosumab and oral bisphosphonates for the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis

Romosozumab versus denosumab in long‐term users of glucocorticoids: A pilot randomized controlled trial

Comparison of Clinical Efficacy and Safety Between Denosumab and Alendronate in Postmenopausal Women with Osteoporosis: a Meta-Analysis

The efficacy and safety of denosumab and bisphosphonates on glucocorticoid induced osteoporosis patients:a meta-analysis

SB16 versus reference denosumab in postmenopausal women with osteoporosis: 18-month outcomes of a phase III randomized clinical trial

Denosumab for osteoporosis in older adults in long‐term care: A randomized trial

Comparison of the Efficacy of Zoledronate and Denosumab in Patients with Acute Osteoporotic Vertebral Compression Fractures: A Randomized Controlled Trial

The Efficacy of Denosumab in Patients With Rheumatoid Arthritis: A Systematic Review and Pooled Analysis of Randomized or Matched Data

A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk

Efficacy and Safety of Denosumab from A Phase Iii, Randomized, Active-Controlled Study Compared with Zoledronic Acid in Patients of Asian Ancestry with Bone Metastases from Solid Tumors.

Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors

Treatment of glucocorticoid-induced osteoporosis with concurrent denosumab and romosozumab: a case report

Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.

The use of denosumab in osteoporosis - an update on efficacy and drug safety

Effect of denosumab , a fully human monoclonal antibody to RANKL , on bone mineral density and fractures : a meta-analysis

Denosumab, for osteoporosis, reduces the incidence of type 2 diabetes, risk of foot ulceration and all‐cause mortality in adults, compared with bisphosphonates: An analysis of real‐world, cohort data, with a systematic review and meta‐analysis

Comparison of romosozumab versus denosumab treatment on bone mineral density after 1 year in rheumatoid arthritis patients with severe osteoporosis: A randomized clinical pilot study

Proposed Denosumab Biosimilar SB16 vs Reference Denosumab in Postmenopausal Osteoporosis: Phase 3 Results Up to Month 12

Efficacy And Safety Of 18 Anti-Osteoporotic Drugs In The Treatment Of Patients With Osteoporosis Caused By Glucocorticoid: A Network Meta-Analysis Of Randomized Controlled Trials